GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Quetiapine immediate-release tablets (adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Seroquel

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Quetiapine immediate-release tablets (adults) - selected U.S. labeling

Product / population
Adult bipolar depression dosing orientation with oral immediate-release quetiapine tablets. Excludes extended-release tablets and other indication-specific titrations.
Renal measure
Indexed ClCr in the renal study; no labeled numeric renal reduction.
Labeled basic dosing

For adult bipolar depression, the label gives once-nightly doses of 50 mg on day 1, 100 mg on day 2, 200 mg on day 3 and 300 mg on day 4; recommended dose 300 mg/day.

Renal information and dialysis

At ClCr 10-30 mL/min/1.73 m2, mean clearance was about 25% lower, but exposures remained within the normal-subject range. The label therefore does not require renal adjustment for those patients. A separate dialysis regimen is not established here.

Selected warnings and limits

Older adults and hepatic impairment have separate dosing considerations. Review orthostasis, sedation, metabolic adverse effects, suicidality and the boxed warning about mortality in elderly patients with dementia-related psychosis.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235f367b-544a-4523-a7bf-a9e2b3aa6fa0

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Quetiapine immediate-release tablets (adults) - selected U.S. labeling

Adult bipolar depression dosing orientation with oral immediate-release quetiapine tablets. Excludes extended-release tablets and other indication-specific titrations.

Renal method: Indexed ClCr in the renal study; no labeled numeric renal reduction.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - SEROQUEL

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Immediate-release quetiapine tablets; selected renal PK/dose comment, not SEROQUEL XR.

Renal method: Source wording: Clcr 10-30 mL/min/1.73 m2; equation not established in selected section.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition - Quetiapine immediate-release tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

Quetiapine immediate-release tablets (adults) - selected U.S. labeling

Adult bipolar depression dosing orientation with oral immediate-release quetiapine tablets. Excludes extended-release tablets and other indication-specific titrations.

Method: Indexed ClCr in the renal study; no labeled numeric renal reduction.

Renal information and dialysisRead this complete source summary
Handbook source

Renal Drug Handbook, fifth edition - Quetiapine immediate-release tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

Historical renal and dialysis observationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeQuetiapine immediate-release tablets (adults) - selected U.S. labelingGlobalRPh RX List - SEROQUELRenal Drug Handbook, fifth edition - Quetiapine immediate-release tablets (adults)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235f367b-544a-4523-a7bf-a9e2b3aa6fa0

Product and population scope

Adult bipolar depression dosing orientation with oral immediate-release quetiapine tablets. Excludes extended-release tablets and other indication-specific titrations.

RDM31-quetiapine-ir-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Quetiapine immediate-release tablets (adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult bipolar depression dosing orientation with oral immediate-release quetiapine tablets. Excludes extended-release tablets and other indication-specific titrations.

Renal method: Indexed ClCr in the renal study; no labeled numeric renal reduction.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

For adult bipolar depression, the label gives once-nightly doses of 50 mg on day 1, 100 mg on day 2, 200 mg on day 3 and 300 mg on day 4; recommended dose 300 mg/day.

RDM31-quetiapine-ir-label-dose · Source locator: 2: Bipolar Depression-Adults

Renal information and dialysis

At ClCr 10-30 mL/min/1.73 m2, mean clearance was about 25% lower, but exposures remained within the normal-subject range. The label therefore does not require renal adjustment for those patients. A separate dialysis regimen is not established here.

RDM31-quetiapine-ir-label-renal · Source locator: 12.3: Renal Insufficiency

Selected warnings and limits

Older adults and hepatic impairment have separate dosing considerations. Review orthostasis, sedation, metabolic adverse effects, suicidality and the boxed warning about mortality in elderly patients with dementia-related psychosis.

RDM31-quetiapine-ir-label-limits · Source locator: Boxed warning; 2; 5

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235f367b-544a-4523-a7bf-a9e2b3aa6fa0
Retrieved
2026-09-05
DailyMed Set ID
235f367b-544a-4523-a7bf-a9e2b3aa6fa0
Renal-function method
Indexed ClCr in the renal study; no labeled numeric renal reduction.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
f00868f00a60d0e62a344fa0e288794a6f6f113087a0c91c4651a783f532fc0b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - SEROQUEL

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Immediate-release quetiapine tablets; selected renal PK/dose comment, not SEROQUEL XR.

Renal method: Source wording: Clcr 10-30 mL/min/1.73 m2; equation not established in selected section.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

In the cited small severe-impairment study, quetiapine exposure remained within the range seen in controls despite reduced mean clearance. The source states no dose adjustment is required for those studied patients. The source prints the studied range as Clcr 10 to 30 mL/min/1.73 m2; retain that unit rather than silently treating it as unindexed Cockcroft-Gault clearance. Dialysis dosing is not established by this excerpt. Hepatic, geriatric and interacting-drug dose modifications remain separate.

RDM35-rxlist-quetiapine-ir-a9aa0e9d23-C1 · Source locator: Clinical Pharmacology: Renal Insufficiency.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/seroquel-drug/
Retrieved
2026-09-07
Renal-function method
Source wording: Clcr 10-30 mL/min/1.73 m2; equation not established in selected section.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
0af1d5ad6149a93d6d85ecd71a449a27fcfb8d3ed36abc6668928f75fbf643be
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Quetiapine immediate-release tablets (adults)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

Across the book's 20-50, 10-20 and below-10 bands, it proposes starting 25 mg/day and increasing by 25-50 mg/day according to response. Dialyzability is listed as unknown for all stated modalities.

RDM31-quetiapine-ir-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

This cautious historical renal initiation differs from the indication-specific label titration. It is not an instruction to blend the two sequences.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 851-852; PDF page(s) 870,871
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235f367b-544a-4523-a7bf-a9e2b3aa6fa0
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
2517e7e65eee28a3b6e2d9e4e7561ff75aa161a5b980670682b9809c03965f7b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235f367b-544a-4523-a7bf-a9e2b3aa6fa0
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
62ea12a0ce55d6e7928342561233e4011b672990d01d0cf61abaec0a622306cf
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report